Contract Pharma

Sino Biopharm Licenses Rovadicitinib to Sanofi for up to $1.5B

Rovadicitinib is approved in China for myelofibrosis and is in late-stage development for chronic graft-versus-host disease.
Seeking Alpha

Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease

Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the marketing authorisation application for Rezurock ...

Imviva Biotech Announces Acceptance of Late-Breaking Abstract Highlighting Data from Ongoing Phase 1/2 Study of CTA313 at 15th European Lupus Meeting

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...
British Journal of Ophthalmology

Evaluation of corneal epithelial thickness mapping via spectral-domain OCT in patients after allogeneic haematopoietic stem cell transplantation

Background Ocular chronic graft versus host disease (oGVHD) seriously affects ocular surface, which often results in corneal ...